Dr. Wang recently founded a drug discovery company--Shenzhen TargetRx, Inc. and serves as its President/CEO. He was the Associate director of Chemistry at ARIAD Pharmaceuticals, Inc. until April 2013. Yihan Wang received his B.Sc. in chemistry from University of Science and Technology of China, and Ph. D. in chemistry from New York University. He then joined ARIAD in 1997, served in its drug discovery department until 2013. His career at ARIAD includes innovative research in therapeutic areas involving bone diseases and cancer, and has been a key contributor to the discovery of several clinical drugs including Ponatinib (IclusigTM) (approved by FDA for resistant CML in Dec 2012), Ridoforolimus (Phase III for Sarcoma and multiple Phase II for other cancers), AP26113 (Phase I/II for NSCLC) and several pre-clinical compounds. Yihan is the primary author of approximately 88 scientific publications, patents and conference abstracts. Yihan is the editor of “Chemical Biology and Drug Design”, and is the reviewers for many professional journals. Yihan co-founded Chinese-American BioMedical Association (CABA) in 2007 and currently is a board director.